I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal CancersPRNewsWire • 06/05/24
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024GlobeNewsWire • 05/23/24
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)PRNewsWire • 11/02/23
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023PRNewsWire • 11/01/23
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503PRNewsWire • 10/10/23
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023PRNewsWire • 08/08/23
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITCPRNewsWire • 07/05/23
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023PRNewsWire • 05/25/23